Please try another search
As of April 4, 2024, Regeneus Ltd was acquired by Cambium Bio Limited, in a reverse merger transaction. Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company’s platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.
Name | Age | Since | Title |
---|---|---|---|
Barry George Sechos | 63 | - | Non-Executive Chairman |
Yu-Hung Tseng | - | 2024 | Non-Executive Director |
Barbara Fant | - | - | Member of Advisory Board |
Gary R. Stevens | - | - | Member of Advisory Board |
Doyle Stulting | - | - | Member of Advisory Board |
Terence Allen Walts | 76 | - | Executive Director |
Edmund K. Waller | - | - | Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review